AngioDynamics FY2026 Revenue Reaches $320M as Med Tech Surges 18%, but Net Loss Widens to $36.7M

summarizeSummary

AngioDynamics posted FY2026 revenue of $320.2M (+9.4% pro forma), led by an 18.4% surge in Med Tech, but the net loss widened to $36.7M. A CEO retirement and restructuring are in progress, even as NanoKnife and thrombectomy platforms advance clinically.

check_boxKey Events · Earnings and Guidance · ANGO

• Record FY2026 Revenue

  Revenue reached $320.2 million, a 9.4% pro forma increase, with Med Tech growing 18.4% to $150.0 million, driven by Auryon, thrombectomy, and NanoKnife.

• Net Loss Widens

  Net loss increased to $36.7 million ($0.88 per share) from $34.0 million in FY2025, as operating expenses rose and restructuring costs continued.

• CEO Retirement Announced

  CEO James Clemmer will retire by November 30, 2026, or upon appointment of a successor; a search is underway, and transition costs of $1.6 million were incurred.

• Manufacturing Restructuring

  The shift to outsourced manufacturing is expected to complete in Q1 FY2027, targeting $15 million in annual cost savings; total restructuring charges to date are $36.4 million.

auto_awesomeAnalysis · ANGO · Industrial Applications And Services

Record FY2026 revenue of $320.2 million was fueled by an 18.4% jump in the Med Tech segment, yet the bottom line remains strained with a net loss of $36.7 million. A CEO transition is underway alongside a manufacturing restructuring that is expected to deliver $15 million in annual savings beginning in FY2027. While positive clinical and regulatory milestones for NanoKnife and the thrombectomy platforms offer growth catalysts, ongoing losses and the leadership change introduce uncertainty.